Immunotherapy in Renal Cell Carcinoma: The Future Is Now

被引：181

作者：

Deleuze, Antoine ^{[1
,2
]}

Saout, Judikael ^{[1
]}

Dugay, Frederic ^{[1
,3
]}

Peyronnet, Benoit ^{[4
]}

Mathieu, Romain ^{[1
,4
]}

Verhoest, Gregory ^{[4
]}

Bensalah, Karim ^{[4
]}

Crouzet, Laurence ^{[2
]}

Laguerre, Brigitte ^{[2
]}

Belaud-Rotureau, Marc-Antoine ^{[1
,3
]}

Rioux-Leclercq, Nathalie ^{[1
,5
]}

Kammerer-Jacquet, Solene-Florence ^{[1
,5
]}

机构：

[1] Univ Rennes, EHESP Ecole Hautes Etud Sante Publ, IRSET Inst Rech Sante Environm & Travail, Inserm,UMR 1085, F-35000 Rennes, France

[2] Ctr Eugene Marquis, Dept Med Oncol, F-35000 Rennes, France

[3] Univ Hosp, Dept Cytogenet, F-35000 Rennes, France

[4] Univ Hosp, Dept Urol, F-35000 Rennes, France

[5] Univ Hosp, Dept Pathol, F-35000 Rennes, France

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2020年 / 21卷 / 07期

关键词：

immunotherapy; immune checkpoint inhibitors; renal cell carcinoma; PD-1; PD-L1; ongoing trials; biomarkers; emerging drugs; TUMOR-CELLS; PD-L1; EXPRESSION; INTERFERON-ALPHA; SUNITINIB; NIVOLUMAB; EVEROLIMUS; RESISTANCE; INHIBITION; RECEPTORS; THERAPIES;

D O I：

10.3390/ijms21072532

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Renal cell carcinoma is the third type of urologic cancer and has a poor prognosis with 30% of metastatic patients at diagnosis. The antiangiogenics and targeted immunotherapies led to treatment remodeling emphasizing the role of the tumour microenvironment. However, long-term responses are rare with a high rate of resistance. New strategies are emerging to improve the efficacy and the emerging drugs are under evaluation in ongoing trials. With the different treatment options, there is an urgent need to identify biomarkers in order to predict the efficacy of drugs and to better stratify patients. Owing to the limitations of programmed death-ligand 1 (PD-L1), the most studied immunohistochemistry biomarkers, and of the tumor mutational burden, the identification of more reliable markers is an unmet need. New technologies could help in this purpose.

引用

页数：22

共 50 条

[41] Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma [J].

Martini, Alberto ;

Fallara, Giuseppe ;

Pellegrino, Francesco ;

Cirulli, Giuseppe Ottone ;

Larcher, Alessandro ;

Necchi, Andrea ;

Montorsi, Francesco ;

Capitanio, Umberto .

WORLD JOURNAL OF UROLOGY, 2021, 39 (05) :1369-1376

[42] Immunotherapy and Radiation Therapy in Renal Cell Carcinoma [J].

Mollica, Veronica ;

Santoni, Matteo ;

Di Nunno, Vincenzo ;

Cimadamore, Alessia ;

Cheng, Liang ;

Lopez-Beltran, Antonio ;

Battelli, Nicola ;

Montironi, Rodolfo ;

Massari, Francesco .

CURRENT DRUG TARGETS, 2020, 21 (14) :1463-1475

[43] Immunotherapy for renal cell carcinoma [J].

Bleumer, I ;

Oosterwijk, E ;

De Mulder, P ;

Mulders, PFA .

EUROPEAN UROLOGY, 2003, 44 (01) :65-75

[44] Immunotherapy in renal cell carcinoma [J].

Heine, Annkristin ;

Holderried, Tobias A. W. ;

Brossart, Peter .

IMMUNOTHERAPY, 2009, 1 (01) :97-107

[45] Evolving Immunotherapy Approaches for Renal Cell Carcinoma [J].

Susanna A. Curtis ;

Justine V. Cohen ;

Harriet M. Kluger .

Current Oncology Reports, 2016, 18

[46] Immunotherapy for Renal Cell Carcinoma [J].

Itsumi, Momoe ;

Tatsugami, Katsunori .

CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2010,

[47] Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: What are we looking for? [J].

Guida, Annalisa ;

Sabbatini, Roberto ;

Gibellini, Lara ;

De Biasi, Sara ;

Cossarizza, Andrea ;

Porta, Camillo .

CANCER TREATMENT REVIEWS, 2021, 94

[48] Individualized therapy for metastatic renal cell carcinoma [J].

Atmaja, Bambang T. ;

Wood, Izabelle ;

Suyanto, Suyanto ;

Sawhney, Paramvir ;

Michael, Agnieszka ;

Pandha, Hardev .

JOURNAL OF CANCER METASTASIS AND TREATMENT, 2021, 7

[49] Advances in treatment of metastatic renal cell carcinoma [J].

Gong, Jun ;

Gerendash, Benjamin ;

Dizman, Nazli ;

Khan, Abrar ;

Pal, Sumanta K. .

CURRENT OPINION IN UROLOGY, 2016, 26 (05) :439-446

[50] The components of tumor microenvironment as biomarker for immunotherapy in metastatic renal cell carcinoma [J].

Su, Jiaming ;

Zhou, Lu ;

Zhang, Zhe ;

Xiao, Xue ;

Qin, Yanning ;

Zhou, Xiaoying ;

Huang, Tingting .

FRONTIERS IN IMMUNOLOGY, 2023, 14

← 1 2 3 4 5 →